Utah Medical Products Inc (UTMD) stock
Close on Nov 16, 2026Market cap $230.38MP/E 22.1Yield –
Earnings
Utah Medical Products's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Utah Medical Products's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 28, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 22, 2026during market hours | $8.62M | -12.1% | $0.88 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026during market hours | $8.53M | -14.3% | $0.84 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 23, 2026during market hours | $8.72M | – | $0.82 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 29, 2026during market hours | $9.04M | -1.2% | $0.80 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 23, 2025during market hours | $9.81M | – | $0.82 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 24, 2025during market hours | $9.95M | – | $0.94 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025during market hours | – | – | $0.92 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 28, 2025during market hours | $9.16M | -25.8% | $0.86 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 30, 2024during market hours | $12.33M | -9.1% | $1.18 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 26, 2023during market hours | $12.51M | – | $1.08 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 25, 2023during market hours | $12.87M | -4.2% | $1.15 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 25, 2023after the close | $12.52M | +1.6% | $1.16 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 31, 2023after the close | $13.58M | +5.1% | $1.25 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 25, 2022during market hours | – | – | $1.18 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022after the close | $13.43M | – | $1.12 | $1.12 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022after the close | $12.32M | – | $0.96 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 2, 2022after the close | $12.91M | – | $1.13 | $1.13 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 26, 2021during market hours | $12.57M | – | $1.15 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 22, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 23, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 28, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 27, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 28, 2020during market hours | – | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | Apr 23, 2020during market hours | – | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Jan 30, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Utah Medical Products's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| consolidated sales decline | FY2026 | +7% | – | New | Oct 22, 2026 |
| sales decline | FY2026 | -13% – -10% | – | New | Jul 23, 2026 |
| litigation expenses | FY2026 | $1.60M | – | New | Jul 23, 2026 |
Guidance history
Every forecast Utah Medical Products put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 22, 2026 | consolidated sales decline | FY2026 | +7% | New |
| Jul 23, 2026 | litigation expenses | FY2026 | $1.60M | New |
| Jul 23, 2026 | sales decline | FY2026 | -13% – -10% | New |
| Oct 23, 2025 | adjusted consolidated EBITDA | FY2025 | $17.00M – $18.00M | New |
| Oct 23, 2025 | total annual consolidated sales | FY2025 | -7% | New |
| Jul 24, 2025 | EBITDA target | FY2025 | $17.00M – $18.00M | Lowered |
| Apr 29, 2025 | adjusted consolidated EBITDA | FY2025 | $18.00M | New |
| Oct 26, 2023 | consolidated sales decline | FY2023 | $2.00M | New |
| Oct 25, 2022 | adjusted consolidated EBITDA | FY2022 | $28.00M | Lowered |
| Feb 1, 2022 | Adjusted consolidated EBITDA | FY2022 | $30.00M | Raised |
| Oct 26, 2021 | adjusted consolidated EBITDA | FY2021 | $26.00M | New |
| Oct 26, 2021 | adjusted consolidated EBITDA | FY2022 | $28.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Utah Medical Products filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Update
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- News
- Results
- Results
- News
See a number that looks wrong?